Online inquiry

IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9656MR)

This product GTTS-WQ9656MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&TNFRSF17 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_001192.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 608
UniProt ID P07766; Q02223
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ9656MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11630MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ8107MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ416MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ15899MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ8323MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ4932MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ10430MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ2197MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALT-803
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW